Soleus Capital Amends Jasper Therapeutics Stake

TL;DR

**Soleus Capital just updated its Jasper Therapeutics stake, watch for potential market reaction.**

AI Summary

Soleus Capital Master Fund, L.P. filed an amended Schedule 13G/A on February 2, 2024, indicating a change in their beneficial ownership of Jasper Therapeutics, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, signaling a potential adjustment in their investment strategy or a change in their ownership percentage, which is important for investors to track as it can influence stock price and market sentiment.

Why It Matters

This filing shows an institutional investor, Soleus Capital, has updated its position in Jasper Therapeutics, which can signal a shift in their confidence in the company's future prospects.

Risk Assessment

Risk Level: medium — Changes in institutional ownership can introduce volatility, especially for smaller biotech companies like Jasper Therapeutics.

Analyst Insight

Investors should monitor subsequent filings from Soleus Capital or other major institutional investors to understand the full scope of their investment changes in Jasper Therapeutics.

Key Players & Entities

• Soleus Capital Master Fund, L.P. (company) — the reporting person filing the SC 13G/A
• Jasper Therapeutics, Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 2, 2024 (date) — the filing date of the SC 13G/A
• 471871202 (number) — the CUSIP number for Jasper Therapeutics, Inc. Common Stock

Forward-Looking Statements

• The market may react to the updated ownership information from Soleus Capital, potentially causing short-term price fluctuations for Jasper Therapeutics. (Jasper Therapeutics, Inc.) — medium confidence, target: Within 1 week

FAQ

Filing Documents

• ea192414-13ga1soleus_jasper.htm (SC 13G/A) — 151KB
• 0001213900-24-009375.txt ( ) — 153KB

From the Filing

SC 13G/A 1 ea192414-13ga1soleus_jasper.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 471871202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 2 of 10 CUSIP NO. 471871202 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital Master Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 987,096 (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 987,096 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 987,096 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.8% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) FI FOOTNOTES (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. These share were also reported after giving effect to a one-for-ten reverse stock split of the Issuer conducted on January 4, 2024 (the “Reverse Split”). (2) This percentage is calculated based upon 11,157,526 shares of common stock outstanding of the Issuer as of October 31, 2023, after giving effect to the Reverse Split, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 that was filed with the Securities and Exchange Commission on November 9, 2023 (the “Form 10-Q”). Page 3 of 10 CUSIP NO. 471871202 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 987,096 (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 987,096 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 987,096 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.8% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO FOOTNOTES (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interes

View Full Filing

View this SC 13G/A filing on SEC EDGAR